Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ISC004
MIFTS: 65

Ischemia

Categories: Cardiovascular diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Ischemia

About this section

MalaCards integrated aliases for Ischemia:

Name: Ischemia 12 55 44 15 73
Acute Coronary Syndrome 44 73

Classifications:

MalaCards categories:
Anatomical: Cardiovascular diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:326
NCIt 50 C34738
SNOMED-CT 68 52674009
Sources

Summaries for Ischemia

About this section
Disease Ontology : 12 A vascular disease that is characterized by a restriction in blood supply to tissues.

MalaCards based summary : Ischemia, also known as acute coronary syndrome, is related to critical limb ischemia and retinal ischemia, and has symptoms including anoxemia, polydipsia and muscle weakness. An important gene associated with Ischemia is LINC01254 (Long Intergenic Non-Protein Coding RNA 1254
Out of the 2,332 lncRNAs assessed, it was identified that 18 lncRNAs were upregulated and 35 lncRNAs were downregulated in patients with MI compared to those with UA. Furthermore, the expression profiles of patients with ACS were compared at different time points and significantly altered lncRNA expression was observed during the progression of ACS. A total of 7 candidate lncRNA biomarkers were identified and an lncRNA-based classifier was developed to predict MI risk based on the expression data of the 7 lncRNAs using random forest and support vector machine strategies. This achieved a classification accuracy of 90.38% with a sensitivity of 100% and a specificity of 68.75%. Additionally, functional analysis suggested that these 7 lncRNAs may be involved in known MI-associated biological processes and pathways.
Dysfunction Pattern: Expression [differentially expressed]), and among its related pathways/superpathways are Development Angiotensin activation of ERK and Pathways in cancer. The drugs Carvedilol and Aspirin have been mentioned in the context of this disorder. Affiliated tissues include heart, brain and endothelial, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Wikipedia : 76 Ischemia or ischaemia is a restriction in blood supply to tissues, causing a shortage of oxygen that is... more...

Sources

Related Diseases for Ischemia

About this section

Diseases related to Ischemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 584)
# Related Disease Score Top Affiliating Genes
1 critical limb ischemia 34.8 HIF1A VEGFA
2 retinal ischemia 34.5 CASP3 CXCL12 HIF1A VEGFA
3 limb ischemia 34.3 ACE CXCL12 HIF1A NOS3 VEGFA
4 microvascular complications of diabetes 5 32.9 ACE NOS3 PON1 VEGFA
5 coronary artery anomaly 32.9 ACE GJA1 NOS3 PON1
6 vascular disease 32.9 ACE HMOX1 MPO NOS3 PON1 VEGFA
7 exudative vitreoretinopathy 1 32.4 EPO HIF1A VEGFA
8 myocardial infarction 31.9 ACE CASP3 CXCL12 GJA1 HIF1A MPO
9 arteries, anomalies of 31.7 ACE NOS3 PON1 VEGFA
10 peripheral artery disease 31.5 ACE NOS3 VEGFA
11 renovascular hypertension 31.0 ACE HMOX1 NOS3
12 diabetes mellitus 30.9 ACE EPO NOS3 PON1 SOD2 VEGFA
13 vascular dementia 30.9 ACE PON1 VEGFA
14 sleep apnea 30.9 ACE NOS3 VEGFA
15 stroke, ischemic 30.9 ACE CASP3 NOS3 PON1
16 diabetic macular edema 30.9 EPO NOS3 VEGFA
17 pulmonary edema 30.6 ACE HMOX1 NOS3
18 hepatopulmonary syndrome 30.4 HMOX1 NOS3 VEGFA
19 pulmonary hypertension 30.3 ACE HIF1A NOS3 VEGFA
20 varicocele 30.3 CASP3 HIF1A NOS3
21 arteriovenous fistula 30.2 EPO HMOX1
22 alzheimer disease 30.2 ACE CASP3 CDK5 HMOX1 MPO NOS3
23 pre-eclampsia 30.0 HIF1A HMOX1 NOS3 VEGFA
24 brain ischemia 12.3
25 transient cerebral ischemia 12.3
26 chronic myocardial ischemia 12.1
27 chronic intestinal vascular insufficiency 11.3
28 cerebral hypoxia 11.3
29 hypoxia 11.2
30 ischemic heart disease 11.2
31 vertebrobasilar insufficiency 11.2
32 myocardial stunning 11.1
33 polyarteritis nodosa, childhood-onset 11.1
34 central retinal vein occlusion 11.1
35 calciphylaxis 11.0
36 microvascular complications of diabetes 1 11.0
37 microvascular complications of diabetes 2 11.0
38 short bowel syndrome 11.0
39 cerebral atherosclerosis 11.0
40 mononeuritis multiplex 11.0
41 renal artery disease 11.0 ACE EPO NOS3
42 chronic mountain sickness 11.0 EPO NOS3 VEGFA
43 hypertensive encephalopathy 11.0 ACE EPO
44 diabetic neuropathy 11.0 ACE EPO SOD2 VEGFA
45 intravascular papillary endothelial hyperplasia 11.0 HIF1A VEGFA
46 hemifacial spasm 11.0 NOS3 VEGFA
47 arteritic anterior ischemic optic neuropathy 11.0 ACE MPO NOS3
48 retinal hemangioblastoma 10.9 CXCL12 HIF1A VEGFA
49 cerebritis 10.9
50 legg-calve-perthes disease 10.9

Graphical network of the top 20 diseases related to Ischemia:



Diseases related to Ischemia
Sources

Symptoms & Phenotypes for Ischemia

About this section

UMLS symptoms related to Ischemia:


anoxemia, polydipsia, muscle weakness, angina pectoris

GenomeRNAi Phenotypes related to Ischemia according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.77 NOL3 PRKAA2 ACE CASP3 HIF1A HMOX1
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.77 MPO NOL3 PRKAA2 ACE CASP3 HIF1A

MGI Mouse Phenotypes related to Ischemia:

46 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.42 ACE ADORA3 CASP3 CXCL12 EGR1 EPO
2 homeostasis/metabolism MP:0005376 10.42 ACE ADORA3 CASP3 CDK5 EGR1 EPO
3 cellular MP:0005384 10.38 CASP3 CXCL12 EGR1 EPO GJA1 HIF1A
4 behavior/neurological MP:0005386 10.37 SOD2 VEGFA ACE ADORA3 CASP3 CDK5
5 hematopoietic system MP:0005397 10.36 ADORA3 CASP3 CXCL12 EGR1 EPO GJA1
6 immune system MP:0005387 10.32 PRKAA2 SOD2 VEGFA ACE ADORA3 CASP3
7 mortality/aging MP:0010768 10.25 HMOX1 HYOU1 MPO NOS3 SOD2 VEGFA
8 endocrine/exocrine gland MP:0005379 10.18 ACE CASP3 EGR1 GJA1 HIF1A HMOX1
9 muscle MP:0005369 10.15 NOS3 PRKAA2 SOD2 VEGFA CASP3 CXCL12
10 integument MP:0010771 10.11 ADORA3 CASP3 CDK5 EGR1 EPO GJA1
11 liver/biliary system MP:0005370 10.09 ACE CXCL12 EGR1 EPO HIF1A HMOX1
12 nervous system MP:0003631 10.06 CASP3 CDK5 CXCL12 EGR1 GJA1 HIF1A
13 renal/urinary system MP:0005367 9.91 ACE ADORA3 CASP3 HIF1A HMOX1 NOS3
14 reproductive system MP:0005389 9.81 EGR1 GJA1 HMOX1 ACE CASP3 CXCL12
15 respiratory system MP:0005388 9.7 NOL3 NOS3 VEGFA ADORA3 CASP3 CDK5
16 vision/eye MP:0005391 9.23 ADORA3 CASP3 EGR1 GJA1 HIF1A NOS3
Sources

Drugs & Therapeutics for Ischemia

About this section

Drugs for Ischemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1237)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carvedilol Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 72956-09-3 2585
2
Aspirin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 50-78-2 2244
3
Clopidogrel Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 120202-66-6, 113665-84-2 60606
4
Ticlopidine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 55142-85-3 5472
5
Cilostazol Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 73963-72-1 2754
6
Probucol Approved, Investigational Phase 4 23288-49-5 4912
7
Sevoflurane Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 28523-86-6 5206
8
Capsaicin Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 404-86-4 1548943
9
Menthol Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 2216-51-5 16666
10
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
11
Valsartan Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 137862-53-4 60846
12
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9005-49-6 772 46507594
13 Nadroparin Approved, Investigational Phase 4 9041-08-1
14
Atenolol Approved Phase 4,Phase 3,Not Applicable 29122-68-7 2249
15
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 1994-09-7, 94-09-7 2337
16
Zinc Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 7440-66-6 23994
17
Nimodipine Approved, Investigational Phase 4,Phase 2,Not Applicable 66085-59-4 4497
18
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 113775-47-6 68602 5311068
19
Esmolol Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 103598-03-4, 81147-92-4 59768
20
Ranolazine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 142387-99-3, 95635-55-5 56959
21
Bevacizumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 216974-75-3
22
Clonidine Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 4205-90-7 2803
23
Rivaroxaban Approved Phase 4,Phase 2,Phase 3,Not Applicable 366789-02-8
24
Ranibizumab Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 347396-82-1 459903
25
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 159351-69-6 6442177
26
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53123-88-9 5284616 6436030 46835353
27
Chlorhexidine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 55-56-1 9552079 2713
28
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 22916-47-8 4189
29
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 128794-94-5 5281078
30
Mycophenolic acid Approved Phase 4,Phase 3,Phase 1,Phase 2 24280-93-1 446541
31
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 53-03-2 5865
32
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 124-94-7 31307
33
Colchicine Approved Phase 4,Phase 3,Phase 2,Not Applicable 64-86-8 6167 2833
34
Abciximab Approved Phase 4,Phase 3,Phase 2,Not Applicable 143653-53-6
35
Bivalirudin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 128270-60-0 16129704
36
Adenosine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 58-61-7 60961
37
Nicorandil Approved, Investigational Phase 4,Phase 3,Not Applicable 65141-46-0 47528
38
Nicardipine Approved, Investigational Phase 4,Phase 3,Not Applicable,Early Phase 1 55985-32-5 4474
39
Udenafil Approved, Investigational Phase 4,Phase 2,Phase 3 268203-93-6 6918523
40
Acarbose Approved, Investigational Phase 4,Phase 3,Not Applicable 56180-94-0 441184
41
Acetylcholine Approved Phase 4,Phase 2,Phase 1,Not Applicable 51-84-3 187
42
Enoxaparin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9005-49-6 772
43
Varenicline Approved, Investigational Phase 4,Phase 3,Not Applicable 249296-44-4 5310966
44
Ticagrelor Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 274693-27-5 9871419
45
Desflurane Approved Phase 4,Phase 3,Not Applicable 57041-67-5 42113
46
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
47
Warfarin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 81-81-2 6691 54678486
48
Methyltestosterone Approved Phase 4,Phase 3,Phase 2 58-18-4 6010
49
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 58-22-0 6013
50
Testosterone enanthate Approved Phase 4,Phase 3,Phase 2 315-37-7 9416

Interventional clinical trials:

(show top 50) (show all 10552)
# Name Status NCT ID Phase Drugs
1 Ischemia In Hemodialysed Patients: Ivabradine Versus Carvedilol Unknown status NCT01425164 Phase 4 Ivabradine;Carvedilol
2 Exploratory Study on the Effects of Early Rosuvastatin Treatment in Patients With Acute Ischemic Stroke Unknown status NCT02643784 Phase 4 Rosuvastatin
3 Clopidogrel for Acute Ischaemia of Recent Onset Unknown status NCT02776540 Phase 4 Clopidogrel;Aspirin
4 PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage Unknown status NCT01013532 Phase 4 Cilostazol;Probucol;Aspirin;placebo of cilostazol;placebo of aspirin
5 The Effectiveness and Safety of Butylphthalide Soft Capsules in Secondary Prevention of Ischemic Stroke Trial Unknown status NCT00724724 Phase 4 Butylphthalide Soft Capsules;Aspirin
6 Effects of Sevoflurane in Subanesthetic Concentrations on the Forearm Perfusion Unknown status NCT00526695 Phase 4 Sevoflurane (Preconditioning)
7 Qutenza for Critical Ischaemia in End Stage Renal Failure Unknown status NCT01704339 Phase 4 QUTENZA
8 Efficacy Study of Huatuo Zaizao Pills in Improving of Neural Function in Acute Ischemic Stroke Unknown status NCT01758536 Phase 4 Huatuo Zaizao Pills
9 Optimized Strategy for Diabetic Patients With Critical Limb Ischemia(Part II) (DCLI-II) Unknown status NCT01173094 Phase 4
10 Valsartan Efficacy on Modest Blood Pressure Reduction in Acute Ischemic Stroke Unknown status NCT00874601 Phase 4 Diovan® (valsartan)
11 PreventIon of IMT Progression in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage-IMT Study Unknown status NCT02483169 Phase 4 cilostazol;Probucol;Aspirin;placebo of cilostazol;Placebo of aspirin
12 Optimized Strategy for Diabetic Patients With Critical Limb Ischemia(Part I) Unknown status NCT01171703 Phase 4
13 Comprehensive Reparative Therapy in Ischemic Stroke COMplex Repair in Ischemic Stroke-Arm Unknown status NCT02581371 Phase 4 Cerebrolysin infusion
14 Safety and Efficacy of Heparin and Nadroparin in the Acute Phase of Ischemic Stroke Unknown status NCT01862978 Phase 4 Heparin;Nadroparin;Placebo
15 Comparison of Peripheral and Cerebral Arterial Flow in Acute Ischemic Stroke: Fimasartan vs. Valsartan vs. Atenolol Unknown status NCT02403349 Phase 4 Fimasartan;Valsartan;Atenolol
16 Comparison of Two Strategies for Glycemic Control in Acute Ischemic Stroke Unknown status NCT00747279 Phase 4 Intensive insulin therapy
17 Efficacy and Safety Study of Nimodipine to Prevent Mild Cognitive Impairment After Acute Ischemic Strokes Unknown status NCT01220622 Phase 4 Nimodipine;Placebo
18 Hemodynamic Response to Intubation Unknown status NCT02844894 Phase 4 Dexmedetomidine;Esmolol;Placebo
19 Preventive Effects of Ginseng Against Atherosclerosis Unknown status NCT02796664 Phase 4
20 Laser Therapy Combined With Intravitreal Aflibercept vs Intravitreal Aflibercept Monotherapy (LADAMO) Unknown status NCT02432547 Phase 4 Aflibercept
21 Sleep Disordered Breathing in Transient Ischemic Attack (TIA)/Ischemic Stroke and Continuous Positive Airway Pressure (CPAP) Treatment Efficacy Unknown status NCT01097967 Phase 4
22 Effect of Ranolazine on Valvular Disease in Patients With Pacemakers Unknown status NCT01979965 Phase 4 Ranolazine (Active drug);Placebo
23 Bevacizumab and Peripheral Retinal Changes on Wide Field Angiography in Diabetic Macular Edema Unknown status NCT02096874 Phase 4 Bevacizumab
24 EPIC (Evaluating Perioperative Ischemia Reduction by Clonidine) Unknown status NCT00335582 Phase 4 clonidine hydrochloride
25 Diagnostic Benefits of HyperQTM vs. Conventional ECG Stress Test. Comparison of HyperQ vs. Stress ECG in Women Before Angiography Unknown status NCT00850486 Phase 4
26 Ranolazine for Improving Symptoms of Palpitations Unknown status NCT01495520 Phase 4 Ranolazine;Placebo
27 Surgical Treatment of Ischemic Mitral Regurgitation Unknown status NCT01368575 Phase 4
28 The Safety and Efficacy Study of High Dose Atorvastatin After Thrombolytic Treatment in Acute Ischemic Stroke Unknown status NCT02452502 Phase 4
29 A Clinical Trial of Danhong Injection in Treating Acute Ischemic Stroke Unknown status NCT02152280 Phase 4 Danhong Injection;Normal Saline
30 Medical and Endovascular Treatment of Atherosclerotic Renal Artery Stenosis (METRAS Study) Unknown status NCT01208714 Phase 4 Optimal medical therapy
31 Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study Unknown status NCT02642419 Phase 4 Rivaroxaban and single antiplatelet drug (aspirin, clopidogrel or prasugrel);Rivaroxaban
32 Evaluation of the "Treat-and-extend" Scheme in Patients With Retinal Vein Occlusion (RVO) With and Without LASER Treatment of Ischaemic Retinal Areas Unknown status NCT02522897 Phase 4 Ranibizumab
33 A Prospective Multicenter Trial Evaluating Helios Biodegradable Polymer SES Safety and Effectiveness in CAD Treatment Unknown status NCT01880879 Phase 4
34 A Study to Evaluate Safety and Efficacy of the ExcelTM Sirolimus Eluting Stent With a Biodegradable Polymer Versus Sirolimus Eluting Stent With Non-Biodegradable Polymer in the Treatment of Patients With de Novo Coronary Artery Lesions Unknown status NCT00825773 Phase 4
35 Safety Study of Melatonin in Stroke Patients Unknown status NCT01863277 Phase 4 Melatonin;placebo
36 Revascularization in Heart Failure Trial – REHEAT 2 Unknown status NCT00388245 Phase 4
37 Effects of the Use of "de Novo" Everolimus in Renal Tranplant Population Unknown status NCT01663805 Phase 4 Everolimus
38 Efficacy of Xience/Promus Versus Cypher in rEducing Late Loss After stENTing Unknown status NCT00698607 Phase 4 6-month clopidogrel therapy;12-month clopidogrel therapy
39 Study Tests Whether a Standardized LVR Performed With the Blue Egg Device Improves Cardiopulmonary Exercise Capacity Unknown status NCT00326690 Phase 4
40 Colchicine for Acute Coronary Syndromes Unknown status NCT01906749 Phase 4 Colchicine;Placebo
41 Cerebral Artery Stenosis, Coronary Artery Disease and Arrhythmia Unknown status NCT00247533 Phase 4
42 Ranolazine Loading to Prevent PCI-induced Myocardial Injury Unknown status NCT01491061 Phase 4 Ranolazine;Placebo
43 Bivalirudin/Prasugrel Versus Abciximab/Clopidogrel in Patients Presenting With STEMI Unknown status NCT01158846 Phase 4 prasugrel/bivalirudin;clopidogrel/abciximab
44 Revascularization of Renal Artery Stenosis Versus Medical Therapy for the Treatment of Ischemic Nephropathy Unknown status NCT01023373 Phase 4 Medical treatment
45 Comparison of Hyperemic Efficacy Between Nicorandil and Adenosine for Fractional Flow Reserve (FFR) Measurement Unknown status NCT01331902 Phase 4
46 Outcomes of Non-infected Diabetic Foot Ulcers With/Without Antibiotics Unknown status NCT01418456 Phase 4 antibiotics
47 Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - SAfety & EffectiveneSS of Drug-ElUting Stents & Anti-platelet REgimen Unknown status NCT01267734 Phase 4 Triple anti-platelet therapy (TAT);Double-dose clopidogrel anti-platelet therapy (DDAT)
48 ASCEND: A Study of Cardiovascular Events iN Diabetes Unknown status NCT00135226 Phase 4 aspirin;Omega-3-acid Ethyl Esters;Placebo Aspirin;Placebo omega-3-Ethyl Esters
49 IV Double and Triple Concentrated Nicardipine for Stroke and ICH Unknown status NCT00325793 Phase 4 Nicardipine
50 Study to Assess Efficacy of Nicorandil+Atenolol vs Atenolol in Treatment of Chronic Stable Angina. Unknown status NCT01397994 Phase 4 Nicorandil;Atenolol

Search NIH Clinical Center for Ischemia

Cochrane evidence based reviews: ischemia

Sources

Genetic Tests for Ischemia

About this section
Sources

Anatomical Context for Ischemia

About this section

MalaCards organs/tissues related to Ischemia:

41
Heart, Brain, Endothelial, Kidney, Bone, Testes, Spinal Cord
Sources

Publications for Ischemia

About this section

Articles related to Ischemia:

(show top 50) (show all 8347)
# Title Authors Year
1
Neutralization of CD95 ligand protects the liver against ischemia-reperfusion injury and prevents acute liver failure. ( 29374146 )
2018
2
Prostaglandin E1 Preconditioning Attenuates Liver Ischemia Reperfusion Injury in a Rat Model of Extrahepatic Cholestasis. ( 29511679 )
2018
3
Human primary CD34<sup>+</sup> cells transplantation for critical limb ischemia. ( 29893031 )
2018
4
Acute Limb Ischemia Secondary to Native Artery Occlusion: Results of a Contemporary Case Series. ( 29404750 )
2018
5
Mechanism of Tau Hyperphosphorylation Involving Lysosomal Enzyme Asparagine Endopeptidase in a Mouse Model of Brain Ischemia. ( 29689717 )
2018
6
Neuroprotective effects of valproic acid on brain ischemia are related to its HDAC and GSK3 inhibitions. ( 29452136 )
2018
7
Critical Role of Flavin and Glutathione in Complex I-Mediated Bioenergetic Failure in Brain Ischemia/Reperfusion Injury. ( 29643256 )
2018
8
Efficacy Outcomes of Endovascular Versus Surgical Revascularization in Critical Limb Ischemia: Results From a Prospective Cohort Study. ( 29355026 )
2018
9
Carotid ergotism with retinal ischemia. ( 29708216 )
2018
10
Electroacupuncture preconditioning protects against focal cerebral ischemia/reperfusion injury<i>via</i>suppression of dynamin-related protein 1. ( 29451211 )
2018
11
Acute Limb Ischemia-Much More Than Just a Lack of Oxygen. ( 29373539 )
2018
12
A case of pheochromocytoma crisis simulating acute coronary syndrome and multiple organ dysfunction syndrome. ( 29452308 )
2018
13
Arginine administration increases circulating endothelial progenitor cells and attenuates tissue injury in a mouse model of hind limb ischemia/reperfusion. ( 29960153 )
2018
14
Lower limb ischemia due to popliteal artery compression by Baker cyst. ( 29942891 )
2018
15
The clinical significance of echo-attenuated plaque in stable angina pectoris compared with acute coronary syndromes: A combined intravascular ultrasound and optical coherence tomography study. ( 29908828 )
2018
16
Astrocytic gap junction inhibition by carbenoxolone enhances the protective effects of ischemic preconditioning following cerebral ischemia. ( 29976213 )
2018
17
Incidence, timing, and type of first and recurrent ischemic events in patients with and without peripheral artery disease after an acute coronary syndrome. ( 29910052 )
2018
18
Management of hyperglycemia during and in the immediate follow-up of acute coronary syndrome. ( 29910582 )
2018
19
Irisin Protects Heart Against Ischemia-Reperfusion Injury Through a SOD2-Dependent Mitochondria Mechanism. ( 29979350 )
2018
20
Corrigendum: The neuroprotective action of dexmedetomidine on apoptosis, calcium entry and oxidative stress in cerebral ischemia-induced rats: Contribution of TRPM2 and TRPV1 channels. ( 29972150 )
2018
21
Lower extremity bypass and endovascular intervention for critical limb ischemia fail to meet Society for Vascular Surgery's objective performance goals for limb-related outcomes in a contemporary national cohort. ( 29937289 )
2018
22
Cardiac Troponin T Concentrations, Reversible Myocardial Ischemia, and Indices of Left Ventricular Remodeling in Patients with Suspected Stable Angina Pectoris: a DOPPLER-CIP Substudy. ( 29959147 )
2018
23
The protective effect of alpha-lipoic acid against brain ischemia and reperfusion injury via mTOR signaling pathway in rats. ( 29432779 )
2018
24
Rationale and design of the SAIL trial for intramuscular injection of allogeneic mesenchymal stromal cells in no-option critical limb ischemia. ( 29242062 )
2018
25
Natural language processing of clinical notes for identification of critical limb ischemia. ( 29425639 )
2018
26
Self-retaining barbed suture reduces warm ischemia time during laparoscopic partial nephrectomy. ( 29448861 )
2018
27
cGAS-mediated autophagy protects the liver from ischemia/reperfusion injury independent of STING. ( 29446653 )
2018
28
Spinal Cord Stimulation Improves the Microvascular Perfusion Insufficiency Caused by Critical Limb Ischemia. ( 29377343 )
2018
29
Effect of Intramuscular Administration of Mesenchymal Stem Cells and Erythropoietin on Angiogenesis in Critical Limb Ischemia. ( 29796803 )
2018
30
Giant coronary aneurysm culprit of an acute coronary syndrome. ( 29317116 )
2018
31
A case of extreme weight loss due to mesenteric ischemia and antiphospholipid syndrome. ( 29881563 )
2018
32
Ketamine ameliorates ischemia-reperfusion injury after liver autotransplantation by suppressing activation of Kupffer cells in rats. ( 29975111 )
2018
33
Initiation of the inflammatory response after renal ischemia/reperfusion injury during renal transplantation. ( 29974405 )
2018
34
Long-Term Clinical Outcomes Survey of Bone Marrow-Derived Cell Therapy in Critical Limb Ischemia in Japan. ( 29386474 )
2018
35
OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY OF ACUTE MACULAR NEURORETINOPATHY REVEALS DEEP CAPILLARY ISCHEMIA. ( 29561336 )
2018
36
Acute limb ischemia of the lower extremity associated with left upper lobe surgery for primary lung cancer. ( 29942889 )
2018
37
Blood rheology of angina pectoris patients with myocardial injury after ischemia reperfusion and its effect on thromboxane B<sub>2</sub>levels. ( 29399084 )
2018
38
Simultaneous Hybrid Operation Common Femoral Endarterectomy and Endovascular Treatment in Multilevel Peripheral Arterial Disease with Critical Limb Ischemia. ( 29915480 )
2018
39
Acute and long-term NCX activation reduces brain injury and restores behavioral functions in mice subjected to neonatal brain ischemia. ( 29551690 )
2018
40
Clinical significance of perioperative changes in ankle-brachial index with regard to extremity-related outcome in non-diabetic patients with critical limb ischemia. ( 29911291 )
2018
41
Genistein attenuates brain damage induced by transient cerebral ischemia through up-regulation of Nrf2 expression in ovariectomized rats. ( 29688134 )
2018
42
Rationale and design of the Clinical and Histologic Analysis of Mesenchymal Stromal Cells in AmPutations (CHAMP) trial investigating the therapeutic mechanism of mesenchymal stromal cells in the treatment of critical limb ischemia. ( 29395424 )
2018
43
Dual Antiplatelet Therapy Guided by CYP2C19 Polymorphisms after Implantation of Second-Generation Drug-Eluting Stents for Management of Acute Coronary Syndrome. ( 29279531 )
2018
44
Relationship between Optical Intensity on Optical Coherence Tomography and Retinal Ischemia in Branch Retinal Vein Occlusion. ( 29942024 )
2018
45
Regulation and mechanism of miR-146 on renal ischemia reperfusion injury. ( 29441948 )
2018
46
Dexmedetomidine Preconditioning Ameliorates Inflammation and Blood-Spinal Cord Barrier Damage after Spinal Cord Ischemia-Reperfusion Injury by Down-Regulation High Mobility Group Box 1-Toll-Like Receptor 4-Nuclear Factor I_B Signaling Pathway. ( 29975331 )
2018
47
The Role of miR-126 in Critical Limb Ischemia Treatment Using Adipose-Derived Stem Cell Therapeutic Factor Concentrate and Extracellular Matrix Microparticles. ( 29371587 )
2018
48
Gene-Modified Mesenchymal Stem Cell-Based Therapy In Renal Ischemia-Reperfusion Injury. ( 29446737 )
2018
49
Layer-specific global longitudinal strain reveals impaired cardiac function in patients with reversible ischemia. ( 29446126 )
2018
50
MicroRNA-19 restores vascular endothelial cell function in lower limb ischemia-reperfusion injury through the KLF10-dependent TGF-I^1/Smad signaling pathway in rats. ( 29953651 )
2018
Sources

Variations for Ischemia

About this section

Copy number variations for Ischemia from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 72977 12 89000000 92600000 Copy number GALNT4 Acute coronary syndrome
Sources

Expression for Ischemia

About this section
Search GEO for disease gene expression data for Ischemia.
Sources

Pathways for Ischemia

About this section

Pathways related to Ischemia according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Development Angiotensin activation of ERK 22
Show member pathways
 12.8 ADORA3 CASP3 CXCL12 EGR1 EPO NOS3
2
Pathways in cancer 37
12.65 CASP3 CXCL12 EPO HIF1A HMOX1 VEGFA
3
G-protein signaling Ras family GTPases in kinase cascades (scheme) 22
Show member pathways
 12.09 CASP3 EGR1 HIF1A VEGFA
4
Brain-Derived Neurotrophic Factor (BDNF) signaling pathway 1
11.98 CASP3 CDK5 EGR1 PRKAA2
5
Fluid shear stress and atherosclerosis 37
11.95 HMOX1 NOS3 PRKAA2 VEGFA
6
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
11.87 CASP3 EGR1 GJA1 HIF1A VEGFA
7
Signaling events mediated by VEGFR1 and VEGFR2 1
Show member pathways
 11.73 HIF1A NOS3 VEGFA
8
Angiogenesis (CST) 4
11.71 HIF1A HMOX1 NOS3
9
AGE-RAGE signaling pathway in diabetic complications 37
11.7 CASP3 EGR1 NOS3 VEGFA
10
Corticotropin-releasing hormone signaling pathway 1
11.59 CASP3 GJA1 NOS3 PRKAA2
11
AGE/RAGE pathway 1
11.55 CASP3 HIF1A NOS3
12
Hepatitis C and Hepatocellular Carcinoma 1
11.43 CASP3 HIF1A VEGFA
13
HIF-1 signaling pathway 37
11.35 EPO HIF1A HMOX1 NOS3 VEGFA
14
Photodynamic therapy-induced HIF-1 survival signaling 1
11.24 EPO HIF1A VEGFA
15
HIF1Alpha Pathway 64
11.19 EPO HIF1A NOS3 VEGFA
16
Validated transcriptional targets of AP1 family members Fra1 and Fra2 1
11.18 GJA1 HMOX1 NOS3
17
Development_Leptin signaling via JAK/STAT and MAPK cascades 22
Show member pathways
 11.09 EGR1 HIF1A VEGFA
18
Angiogenesis (WikiPathways) 1
10.92 HIF1A NOS3 VEGFA
19
HIF-1-alpha transcription factor network 1
10.83 CXCL12 EPO HIF1A HMOX1 VEGFA
20
miR-148a/miR-31/FIH1/HIF1andalpha;-Notch signaling in glioblastoma 1
10.53 HIF1A VEGFA
Sources

GO Terms for Ischemia

About this section

Biological processes related to Ischemia according to GeneCards Suite gene sharing:

(show all 36)
# Name GO ID Score Top Affiliating Genes
1 angiogenesis GO:0001525 9.96 HIF1A HMOX1 NOS3 VEGFA
2 negative regulation of gene expression GO:0010629 9.94 GJA1 HIF1A PRKAA2 VEGFA
3 neuron migration GO:0001764 9.85 CDK5 CXCL12 GJA1
4 mitochondrion organization GO:0007005 9.84 CDK5 NOS3 SOD2
5 positive regulation of angiogenesis GO:0045766 9.84 HIF1A HMOX1 NOS3 VEGFA
6 response to glucose GO:0009749 9.83 CASP3 EGR1 GJA1
7 response to wounding GO:0009611 9.82 ADORA3 CASP3 CDK5
8 positive regulation of endothelial cell proliferation GO:0001938 9.81 CXCL12 HIF1A VEGFA
9 regulation of macroautophagy GO:0016241 9.8 CASP3 CDK5 PRKAA2
10 cellular response to hypoxia GO:0071456 9.8 HIF1A HMOX1 HYOU1 VEGFA
11 response to lipopolysaccharide GO:0032496 9.8 CASP3 EPO GJA1 MPO NOS3
12 positive regulation of blood vessel endothelial cell migration GO:0043536 9.76 HIF1A NOS3 VEGFA
13 blood vessel remodeling GO:0001974 9.69 ACE NOL3 NOS3
14 regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061418 9.67 EGR1 EPO HIF1A VEGFA
15 induction of positive chemotaxis GO:0050930 9.66 CXCL12 VEGFA
16 negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway GO:1902176 9.66 NOL3 SOD2
17 positive regulation of macroautophagy GO:0016239 9.65 HIF1A HMOX1 PRKAA2
18 response to fluid shear stress GO:0034405 9.64 GJA1 NOS3
19 positive regulation of chemokine biosynthetic process GO:0045080 9.62 EGR1 HMOX1
20 regulation of blood pressure GO:0008217 9.62 ACE HMOX1 NOS3 SOD2
21 oxygen homeostasis GO:0032364 9.61 HIF1A SOD2
22 positive regulation of axon extension involved in axon guidance GO:0048842 9.61